EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Functional Connectivity Mechanisms Underlying Symptom Reduction Following Lisdexamfetamine Treatment in Binge-Eating Disorder: A Clinical Trial

Kristi R Griffiths, Isabella A Breukelaar, Grace Harvie, Jenny Yang, Sheryl L Foster, Anthony W Harris, Simon Clarke, Phillipa J Hay, Stephen Touyz, Mayuresh S Korgaonkar, Michael R Kohn

Biological Psychiatry Global Open Science · 2024-01 · 4 (1) · 317-325

DOI: 10.1016/j.bpsgos.2023.08.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological Psychiatry Global Open Science, 2024-01. Verfasst von Kristi R Griffiths und 10 weiteren Autor:innen. Beteiligte Einrichtung: Brain Dynamics Centre, Westmead Institute for Medical Research, The University of Sydney, Westmead, New South Wales, Australia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health and Medical Research Council, Takeda Pharmaceutical Company, New South Wales Institute of Psychiatry.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Speculation exists as to whether lisdexamfetamine dimesylate (LDX) acts on the functional connectivity (FC) of brain networks that modulate appetite, reward, or inhibitory control in binge-eating disorder (BED). Better insights into its action may help guide the development of more targeted therapeutics and identify who will benefit most from this medication. Here, we use a comprehensive data-driven approach to investigate the brain FC changes that underlie the therapeutic action of LDX in patients with BED.

Methods

Forty-six participants with moderate to severe BED received LDX titrated to 50 or 70 mg for an 8-week period. Twenty age-matched healthy control participants were also recruited. Resting-state functional magnetic resonance imaging was used to probe changes in brain FC pre- and post treatment and correlated with change in clinical measures.

Results

Ninety-seven percent of trial completers (n = 31) experienced remission or a reduction to mild BED during the 8-week LDX trial. Widespread neural FC changes occurred, with changes in default mode to limbic, executive control to subcortical, and default mode to executive control networks associated with improvements in clinical outcomes. These connections were not distinct from control participants at pretreatment but were different from control participants following LDX treatment. Pretreatment connectivity did not predict treatment response.

Conclusions

FC between networks associated with self-referential processing, executive function, and reward seem to underlie the therapeutic effect of LDX in BED. This suggests that LDX activates change via multiple systems, with most changes in compensatory networks rather than in those characterizing the BED diagnosis.

Schlagwörter

Stichwörter der Autor:innen

Binge-eating disorderClinical trialData-drivenDefault mode networkFunctional connectivityLisdexamfetamine

Autor:innen und Institutionen

  • Brain Dynamics Centre, Westmead Institute for Medical Research, The University of Sydney, Westmead, New South Wales, Australia.
  • InsideOut Institute, University of Sydney, Sydney Local Health District, Sydney, New South Wales, Australia.
  • School of Psychology, University of New South Wales, Sydney, New South Wales, Australia.
  • Department of Radiology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Specialty of Psychiatry, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Centre for Research into Adolescents' Health, University of Sydney, Sydney, New South Wales, Australia.

Förderung

  • National Health and Medical Research Council
  • Takeda Pharmaceutical Company
  • New South Wales Institute of Psychiatry
  • University of Sydney
  • Australian Medical Council
  • Australian Research Council
  • Balnaves Foundation

Zitieren

APA

Griffiths, K. R., Breukelaar, I. A., Harvie, G., Yang, J., Foster, S. L., Harris, A. W., Clarke, S., Hay, P. J., Touyz, S., Korgaonkar, M. S., & Kohn, M. R. (2024). Functional Connectivity Mechanisms Underlying Symptom Reduction Following Lisdexamfetamine Treatment in Binge-Eating Disorder: A Clinical Trial. Biological Psychiatry Global Open Science, 4(1), 317-325. https://doi.org/10.1016/j.bpsgos.2023.08.016

Vancouver

Griffiths KR, Breukelaar IA, Harvie G, Yang J, Foster SL, Harris AW, et al. Functional Connectivity Mechanisms Underlying Symptom Reduction Following Lisdexamfetamine Treatment in Binge-Eating Disorder: A Clinical Trial. Biological Psychiatry Global Open Science. 2024;4(1):317-325. doi:10.1016/j.bpsgos.2023.08.016

BibTeX
@article{Griffiths2024,
  author = {Griffiths, Kristi R and Breukelaar, Isabella A and Harvie, Grace and Yang, Jenny and Foster, Sheryl L and Harris, Anthony W and Clarke, Simon and Hay, Phillipa J and Touyz, Stephen and Korgaonkar, Mayuresh S and Kohn, Michael R},
  title = {Functional Connectivity Mechanisms Underlying Symptom Reduction Following Lisdexamfetamine Treatment in Binge-Eating Disorder: A Clinical Trial},
  journal = {Biological Psychiatry Global Open Science},
  year = {2024},
  volume = {4},
  number = {1},
  pages = {317--325},
  doi = {10.1016/j.bpsgos.2023.08.016}
}
Kostenlos starten →